Keyphrases
Regenerable
100%
Aptasensor
100%
Continuous Monitoring Systems
100%
Bevacizumab
50%
In Situ
50%
Therapeutic Antibody
50%
Aptamer
44%
Azobenzene
33%
Monoclonal Antibody
27%
Anti-idiotype
16%
Biosensing Technology
11%
Conformational Shifts
11%
Binding Site
11%
FDA-approved Drugs
11%
Chronic Conditions
11%
Autoimmune Disease
11%
Continuous Monitoring
11%
Cis-trans Photoisomerization
11%
IgG1
11%
Chaotropic
11%
Therapeutic Monoclonal Antibody
11%
Infectious Diseases
11%
In Situ Regeneration
11%
Cancer Types
11%
Reversible Structural Change
11%
Titration
5%
Electrochemical Sensor
5%
Vascular Endothelial Growth Factor
5%
Technology Development
5%
Review Criteria
5%
Dissociation
5%
Dissociation Constant
5%
Biomolecular Engineering
5%
In Vivo Monitoring
5%
In Vivo Applications
5%
Undergraduate Courses
5%
Promising Treatment
5%
Coursework
5%
UV Exposure
5%
Biological Fluids
5%
Human IgG
5%
Patient-specific
5%
Humanized
5%
Cancer Disease
5%
Pharmacokinetics
5%
Light Sensitive
5%
Interdisciplinary Research
5%
Regeneration
5%
Conformational Change
5%
Impact Review
5%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
100%
Therapeutic Antibodies
50%
Aptamer
50%
Monoclonal Antibody
33%
Genetic Engineering and Gene Technology
11%
Light Exposure
11%
Binding Site
11%
Dissociation Constant
5%
Conformational Change
5%
Pharmacokinetics
5%
Liquid
5%
Biochemistry
5%
Vascular Endothelial Growth Factor A
5%
Immunology and Microbiology
Bevacizumab
100%
Therapeutic Antibodies
50%
Monoclonal Antibody
33%
Antiidiotypic Antibody
16%
Light Exposure
11%
Dissociation Constant
11%
Genetic Engineering and Gene Technology
11%
Binding Site
11%
Immunoglobulin G1
5%
Pharmacokinetics
5%
Vasculotropin A
5%
Conformational Transition
5%
Liquid
5%